The guidelines recommend the use of postpartum tranexamic acid (25 mg/kg TID for 10–14 days) in women with type 1 von Willebrand disease or low von Willebrand factor levels, including extended prophylaxis to reduce the risk of secondary postpartum haemorrhage, and affirming its safety during breastfeeding [26]. This evidence concerns the gene VWF and von Willebrand disease 1.